Overall, T-Dxd may be the first HER2-targeted therapy approved for HER2-low BC patients, based on the strong preclinical rationale, encouraging early efficacy signs hitherto discussed, and its current stage of development. This evidence concerns the gene ERBB2 and breast cancer.